Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Publication year range
1.
Zhonghua Liu Xing Bing Xue Za Zhi ; 38(4): 531-536, 2017 Apr 10.
Article in Chinese | MEDLINE | ID: mdl-28468077

ABSTRACT

Objective: To detect the changes in the immune function of opioid-dependent subjects during the withdrawal stage through the administration of Jitai tablet. Methods: Subjects were treated as Jitai tablet alone, Jitai tablet plus buprenorphine and placebo, in a randomized,double-blind, placebo-controlled trial. Before and after the 14(th) day of withdrawal, levels of immunoglobulin (IgM, IgA, IgG), T cell subsets (CD(3)(+), CD(4)(+), CD(8)(+), CD(4)(+)/CD(8)(+)) and cytokines (IL-2, IFN-γ, IL-4, IFN-γ/IL-4) were detected. Results: Compared with healthy people, immunity function before withdrawal among the opioid abusers showed higher levels of IgM, IL-2, IFN-γ, IL-4 and lower level of CD(3)(+)T, as (1.67±0.87) g/L, (14.44±13.50)%, (20.23±15.10)%, (1.97±1.59)%, (47.01±13.62)%, respectively, with difference statistically significant (P<0.05). There was no big difference of other immunity indicators between the two groups (P>0.05). At the 14(th) day of withdrawal in placebo group, levels of IL-4 returned to normal while IFN-γ/IL-4 ratio increased by 3.43 times (P<0.05). Levels of IgA, IgG, CD(4)(+) and CD(4)(+)/CD(8)(+) ratio fluctuated within normal range. There were no significant changes in other immunity indicators (P>0.05). Compared with placebo group, fluctuation of IgG and IgM decreased in Jitai group during withdrawal period, together with a normal level of IgM at the 14(th) day. Level of IL-4 abnormally rose up by 0.54 times in Jitai tablet plus buprenorphine group, while IFN-γ/IL-4 ratio been switched back at the 14(th) day of withdrawal. Other immune indicators were not affected by medical interventions. Conclusion: We noticed that certain impairment of the immune function might be restored by Jitai tablet during the withdrawal period.


Subject(s)
Buprenorphine/therapeutic use , Drugs, Chinese Herbal/therapeutic use , Immunity/drug effects , Narcotic Antagonists/therapeutic use , Opioid-Related Disorders/blood , Opioid-Related Disorders/drug therapy , Substance Withdrawal Syndrome/blood , Substance Withdrawal Syndrome/drug therapy , Cytokines/blood , Double-Blind Method , Humans , Immunity/physiology , Immunoglobulins/blood , Interferon-gamma/blood , Interleukin-2/blood , Male , Tablets
2.
Bioorg Med Chem ; 9(7): 1739-46, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11425575

ABSTRACT

A series of vanilloid-type beta-adrenoceptor blockers derived from antioxidant traditional Chinese herbal medicines were synthesized and tested for their antioxidant and adrenoceptor antagonistic activities. They all possessed significant beta-adrenoceptor blocking activities under in vitro experiments and radioligand binding assays. In addition, some compounds were further examined in in vivo tests and produced antagonist effects matching that of propranolol and labetalol by measurements of antagonism toward (-)isoproterenol-induced tachycardia and (-)phenylephrine-induced pressor responses in anesthetized rats. Furthermore, all of the compounds had antioxidant effects inherited from their original structures. In conclusion, compound 11 had the most potent beta-adrenoceptors blocking activity, 12 and 13 possessed high cardioselectivity, whereas 14, 15 and 16 possessed additional alpha-adrenoceptor blocking activity and 15 is the most effective antioxidant of all. The antioxidant activity may be due to their alpha and beta unsaturated side chain at position 1 and ortho-substituted methoxy moiety on 4-phenoxyethylamine.


Subject(s)
Adrenergic beta-Antagonists/chemical synthesis , Adrenergic beta-Antagonists/pharmacology , Antioxidants/chemical synthesis , Antioxidants/pharmacology , Adrenergic beta-Antagonists/metabolism , Animals , Antioxidants/metabolism , Brain/drug effects , Brain/metabolism , Guinea Pigs , In Vitro Techniques , Lipid Peroxidation , Magnetic Resonance Spectroscopy , Radioligand Assay , Rats , Rats, Wistar
3.
Int J Oncol ; 12(3): 617-20, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9472101

ABSTRACT

In a breast cancer cell line, MDA-MB-468, established in our laboratory, an average of 3% of the mitotic cells exhibited a phenomenon known as centromere splaying, which is a characteristic feature of cells of patients with Roberts syndrome. However, centromere splaying in cells of Roberts syndrome patients is limited to i) the centromere region and ii) chromosomes with large amounts of heterochromatin. When the breast cancer cells were treated with an extract of green tea GTE-TP91, up to 45% of the metaphases were observed to exhibit this behavior; and the precocious centromere separation was highly exaggerated, affecting all chromosomes in such metaphases. Apparently, as the sister centromeres continued to pull apart, they carried the chromatids with them, except for the telomere regions, giving a ring-like configuration. Eventually, the sister chromatids became completely separated. Whether this bizarre phenomenon was induced by the polyphenols contained in this green tea extract GTE-TP91 is not known, but this phenomenon, upon further investigation, may throw some light on chromosomal proteins, centromere behavior, telomere behavior and related questions.


Subject(s)
Breast Neoplasms/pathology , Centromere/drug effects , Tea , Breast Neoplasms/genetics , Cell Division/drug effects , Centromere/genetics , Centromere/pathology , Female , Humans , Karyotyping , Mitosis , Tumor Cells, Cultured
4.
Basic Life Sci ; 36: 491-505, 1985.
Article in English | MEDLINE | ID: mdl-4096703

ABSTRACT

There is an increasing interest in developing assay systems that are effective in detecting aneuploidy-producing agents. Because the current methodology for detecting aneuploidy is extremely varied, presently no comparisons of the validity and sensitivity of various assays can be made. This is due to a lack of sufficient data on the testing of the same compounds in multiple systems. Thus, there is an imminent need to select a few model compounds to be tested in all the available assays. This chapter discusses the rationale for the selection of model compounds. Approximately 30 compounds were identified as candidate compounds for various reasons. It is not our intention to discourage studies of compounds not discussed in this chapter. It is merely our effort to facilitate the final selection of a few model compounds to be used for comparative studies in diverse assays or for collaborative studies to determine interlaboratory variation of selected assays.


Subject(s)
Aneuploidy , Teratogens , Animals , Chromosomes/ultrastructure , Crossing Over, Genetic , Drosophila/drug effects , Drosophila/genetics , Drug Evaluation, Preclinical/methods , Fungi/drug effects , Meiosis , Models, Genetic , Mutagenicity Tests/methods , Mutagens/pharmacology , Mutation , Plants/drug effects , Plants/genetics
SELECTION OF CITATIONS
SEARCH DETAIL